We are dedicated to bring the real science to the table.
If you think that our work matters, consider to sustain us with a donation.

DONATE
The Inescapable Immune Escape Pandemic

Charts & Figures associated with the book

References : see below the Charts & Figures

‍

Fig. 1

Fig. 1: The Impact of Vaccination On Immune Escape and CBIIS Training.

_____________________

‍

Fig.2

Fig. 2: Exposure to highly infectious Omicron descendants results in diminished viral shedding and a gradual increase in PNNAb-mediated immune pressure on viral virulence.

_____________________

‍

Fig. 3

Fig.3: SIR-enabling VBTIs drive large-scale viral immune escape in vaccinees by reorienting the immune response to S-associated antigenic sites that prime broadly functional antibodies (Abs) with low affinity.

_____________________

‍

Fig.4

‍

Fig. 4: PNNAb-mediated enhancement of viral infectiousness triggers PNNAb-dependent BTI in vaccinees and may thereby trigger SIR.

_____________________

‍

Fig. 5

‍

Fig. 5: Trained CBII in the unvaccinated (panels A and B) but not in the vaccinated (panels C and D) prevents BTIs from triggering SIR.

_____________________

‍

Fig. 6

‍

Fig. 6: Reverse molecular epidemiology applied to highly vaccinated populations.

_____________________

‍

Fig. 7

‍

Fig. 7: Productive infection with pre-Omicron lineages results in training of the CBIIS and a short-lived increase in pNAb titers.

_____________________

‍

Fig. 8

Fig. 8: Flow chart depicting the evolutionary dynamics of immune escape as initially triggered by mass vaccination.

_____________________

‍

Fig. 9

‍

Fig. 9: Population-level immune pressure on more conserved, immunodominant S-associated epitopes promotes fast and large-scale immune escape.

_____________________

‍

Fig. 10

‍

Fig. 10: Pathogenesis of PNNAb-dependent VBTI.

_____________________

‍

Fig. 11

Fig. 11: Pathogenesis of (PNN)Ab-independent VBTI.

_____________________

‍

Fig. 12

Fig. 12: How C-19 mass vaccination during the SC-2 pandemic turned a natural pandemic into an inescapable SC-2 immune escape pandemic

‍

References associated with the book

Poor virus-neutralizing capacity in highly C-19 vaccinated populations could soon lead to a fulminant spread of SARS-CoV-2 super variants that are highly infectious and highly virulent in vaccinees while being fully resistant to all existing and future spike-based C-19 vaccines 👉🏻

https://cdn.prod.website-files.com/616004c52e87ed08692f5692/627933433cc6dc1c869df8ad_GVB%27s%20analysis%20of%20C-19%20evolutionary%20dynamics%20update%20May%202022.pdf

  1. Kulkarni R. (2019). Antibody-Dependent Enhancement of Viral Infections. Dynamics of Immune Activation in Viral Diseases, 9–41. https://doi.org/10.1007/978-981-15-1045-8_2
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119964/
  2. Liu Y, Soh WT, Kishikawa JI, Hirose M, Nakayama EE, Li S, Sasai M, Suzuki T, Tada A, Arakawa A, Matsuoka S, Akamatsu K, Matsuda M, Ono C, Torii S, Kishida K, Jin H, Nakai W, Arase N, Nakagawa A, Matsumoto M, Nakazaki Y, Shindo Y, Kohyama M, Tomii K, Ohmura K, Ohshima S, Okamoto T, Yamamoto M, Nakagami H, Matsuura Y, Nakagawa A, Kato T, Okada M, Standley DM, Shioda T, Arase H. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021 Jun 24;184(13):3452-3466.e18. doi: 10.1016/j.cell.2021.05.032. Epub 2021 May 24. PMID: 34139176; PMCID: PMC8142859.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142859/
  3. Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K., Lu, X., Parks, R., Sutherland, L. L., Oguin, T. H., 3rd, McDanal, C., Perez, L. G., Mansouri, K., Gobeil, S. M. C., Janowska, K., Stalls, V., Kopp, M., Cai, F., Lee, E., … Saunders, K. O. (2021). In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 184(16), 4203–4219.e32. https://doi.org/10.1016/j.cell.2021.06.021
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232969/
  4. Yahi, N., Chahinian, H., & Fantini, J. (2021). Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?. The Journal of infection, 83(5), 607–635. https://doi.org/10.1016/j.jinf.2021.08.010
    https://pubmed.ncbi.nlm.nih.gov/34384810/
  5. Vanden Bossche, G. (2022). Predictions on evolution Covid 19 pandemic.
    https://www.voiceforscienceandsolidarity.org/scientific-blog/predictions-gvb-on-evolution-c-19-pandemic
  6. Wu, L., Zhou, L., Mo, M. et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Sig Transduct Target Ther 7, 8 (2022). https://doi.org/10.1038/s41392-021-00863-2
    https://www.nature.com/articles/s41392-021-00863-2
  7. Tian, W., Li, D., Zhang, N. et al. O-glycosylation pattern of the SARS-CoV-2 spike protein reveals an “O-Follow-N” rule. Cell Res 31, 1123–1125 (2021). https://doi.org/10.1038/s41422-021-00545-2
    https://www.nature.com/articles/s41422-021-00545-2
  8. Watanabe, Y., Bowden, T. A., Wilson, I. A., & Crispin, M. (2019). Exploitation of glycosylation in enveloped virus pathobiology. Biochimica et biophysica acta. General subjects, 1863(10), 1480–1497. https://doi.org/10.1016/j.bbagen.2019.05.012
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686077/
  9. Shajahan, A., Supekar, N.T., Gleinich, A.S., Azadi, P., (2020) Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology, , Volume 30, Issue 12, December 2020, Pages 981–988
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239183/pdf/cwaa042.pdf)
  10. Kull, K., (2000), Organisms can be proud to have been their own designers. Cybernetics & Human Knowing, Volume 7, Number 1, 1 January 2000, pp. 45-55(11)
    https://www.ingentaconnect.com/content/imp/chk/2000/00000007/00000001/54
  11. Taubenberger, J. K., & Morens, D. M. (2006). 1918 Influenza: the mother of all pandemics. Emerging infectious diseases, 12(1), 15–22. https://doi.org/10.3201/eid1201.050979
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291398/pdf/05-0979.pdf
  12. Patrono, L.V., Vrancken, B., Budt, M. et al. Archival influenza virus genomes from Europe reveal genomic variability during the 1918 pandemic. Nat Commun 13, 2314 (2022). https://doi.org/10.1038/s41467-022-29614-9
    https://www.nature.com/articles/s41467-022-29614-9
                                                                   
                                                                      ❖  ❖  ❖
    ‍
    Within these 57 literature references, 13-32 are a special list (non-exhaustive) of supportive evidence that Geert Vanden Bossche used to develop and validate his hypothesis in this book.
    ‍    ‍
  13. Quandt, J., Muik, A., Salisch, N., Lui, B. G., Lutz, S., Krüger, K., Wallisch, A. K., Adams-Quack, P., Bacher, M., Finlayson, A., Ozhelvaci, O., Vogler, I., Grikscheit, K., Hoehl, S., Goetsch, U., Ciesek, S., Türeci, Ö., & Sahin, U. (2022). Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Science immunology, 7(75), eabq2427. https://doi.org/10.1126/sciimmunol.abq2427
    https://pubmed.ncbi.nlm.nih.gov/35653438/
  14. Wang, Q., Guo, Y., Iketani, S. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603–608 (2022). https://doi.org/10.1038/s41586-022-05053-w
    https://www.nature.com/articles/s41586-022-05053-w
  15. Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N. E., & Walker, L. M. (2022). Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. Science immunology, 7(73), eabq3511. https://doi.org/10.1126/sciimmunol.abq3511
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097882/
  16. Nutalai, R., Zhou, D., Tuekprakhon, A., Ginn, H. M., Supasa, P., Liu, C., Huo, J., Mentzer, A. J., Duyvesteyn, H. M. E., Dijokaite-Guraliuc, A., Skelly, D., Ritter, T. G., Amini, A., Bibi, S., Adele, S., Johnson, S. A., Constantinides, B., Webster, H., Temperton, N., Klenerman, P., … Screaton, G. R. (2022). Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 185(12), 2116–2131.e18. https://doi.org/10.1016/j.cell.2022.05.014
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120130/
  17. Arora, P., Kempf, A., Nehlmeier, I., Schulz, S.R., Cossmann, A., Metodi V Stankov, M.V., Hans-Martin Jäck, H.M., Georg M N Behrens, G.M.N., Stefan Pöhlmann, S., Markus Hoffmann, M., (2022), Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5., The Lancet, Volume 22, Issue 8, August 2022, Pages 1117-1118, https://doi.org/10.1016/S1473-3099(22)00422-4
    https://www.thelancet.com/action/showPdf?pii=S1473-3099%2822%2900422-4
  18. Wratil, P.R., Stern, M., Priller, A. et al., (2022), Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat Med 28, 496–503. https://doi.org/10.1038/s41591-022-01715-4
    https://www.nature.com/articles/s41591-022-01715-4
  19. Muecksch, F., Wang, Z., Cho, A. et al., (2022), Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128–134. https://doi.org/10.1038/s41586-022-04778-y
    https://www.nature.com/articles/s41586-022-04778-y
  20. Munro, A. P. S., Janani, L., Cornelius, V., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dodd, K., Enever, Y., Gokani, K., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., van der Klaauw, A. A., Kwok, J., Lambe, T., COV-BOOST study group (2021). Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet (London, England), 398(10318), 2258–2276. https://doi.org/10.1016/S0140-6736(21)02717-3
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639161/
  21. Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Lingling Yu, Yuxue Gao, Na Zhang, Yao WangFei Shao, Xiaohua Hao, Yanli Xu, Ronghua Jin, Youchun Wang, Xiaoliang Sunney Xie, Yunlong Cao, (2022), Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants, volume 22, issue 11, P1535-1537, https://doi.org/10.1016/S1473-3099(22)00642-9
    https://www.biorxiv.org/content/10.1101/2022.08.09.503384v1.full.pdf
  22. Sugano, A., Takaoka, Y., Kataguchi, H., Kumaoka, M., Ohta, M., Kimura, S., Araki, M., Morinaga, Y., Yamamoto, Y., (2022), SARS-CoV-2 Omicron BA.2.75 variant may be much more infective than preexisting variant, https://doi.org/10.1101/2022.08.25.505217
    https://www.biorxiv.org/content/10.1101/2022.08.25.505217v4.full.pdf
  23. Cao, Y., Jian, F., Wang, J., Yu, Y. Song, W., Yisimayi, A., Wang, J., An, R. Chen, X., Zhang, N., Wang, Y. Wang, P. Zhao, L., Sun, H., Yu, L., Yang, S., Niu, X., Xiao, T., Gu, Q., Shao, F., Hao, X., Xu, Y., Jin, R., Shen, Z., Wang, Y., Xie, X.S., (2022), Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution., https://doi.org/10.1101/2022.09.15.507787
    https://www.biorxiv.org/content/10.1101/2022.09.15.507787v4.full.pdf
  24. Starr, T.N., Greaney, A.J., Stewart, C.M., Walls, A.C., Hannon, W.W., Veesler, D., Bloom, J.D., (2022), Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains., PLoS Pathog 18(11): e1010951. https://doi.org/10.1371/journal.ppat.1010951
    https://www.biorxiv.org/content/10.1101/2022.09.20.508745v1.full.pdf
  25. Muik, A., Lui, B.G., Bacher,, M., Wallisch, A-K., Toker, A., Finlayson, A., Krüger, K., Ozhelvaci, O., Grikscheit, K., Hoehl, S., Ciesek, S., Türeci, Ö., Sahin, U., (2022), Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5., Science Immunology, Vol 7, Issue 77, DOI: 10.1126/sciimmunol.ade2283
    https://www.science.org/doi/epdf/10.1126/sciimmunol.ade2283
  26. Cao, Y., Yisimayi, A., Jian, F. et al., (2022), BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593–602. https://doi.org/10.1038/s41586-022-04980-y
    https://www.nature.com/articles/s41586-022-04980-y
  27. Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K. M., Muñoz Sandoval, D., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., Forooghi, N., Treibel, T. A., Manisty, C., Moon, J. C., COVIDsortium Investigators§, COVIDsortium Immune Correlates Network§, Semper, A., Brooks, T., McKnight, Á., Altmann, D. M., Moon, J. C. (2022). Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science (New York, N.Y.), 377(6603), eabq1841. https://doi.org/10.1126/science.abq1841
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210451/
  28. Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M.S., Lier, M., Dopfer-Jablonka, A., Jäck, H-m., Behrens, G.M.N., (2022), The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic, Cell, Volume 185, Issue 3, Pages 447-456.e11, https://doi.org/10.1016/j.cell.2021.12.032
    https://www.sciencedirect.com/science/article/pii/S0092867421014951
  29. Irrgang, P. Gerling, J., Kocher, K., Lapuente, D., Steininger, P., Habenicht, K., Wytopil, ., Beileke, S., Schäfer, S., Zhong, J., Ssebyatika, G., Krey, T., Falcone, V., Schïmein, C., Peter, A.S. Nganou-Makamdop, K., Hengel, H., Held, J., Bogdan, C. Überla, K., Schober, K., Winkler, T.H., Tenbusch, M., (2022), Class switch towards non-inflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination, DOI: 10.1126/sciimmunol.ade279
    https://www.science.org/doi/10.1126/sciimmunol.ade2798
  30. Witte, L., Baharani, V., Schmidt, F., Wang, Z., Cho, A., Raspe, R., Guzman-Cardozo, M.C., Muecksch, F., Gaebler, C., Caskey, M., Nussenzweig, M.C., Hatziioannou, T., Bieniasz, P.D., (2022), Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape, https://doi.org/10.1101/2022.08.17.504313
    https://www.biorxiv.org/content/10.1101/2022.08.17.504313v1.full.pdf
  31. Kaku, C.I., Starr, T.N., Zhou, P., Dugan, H.L., Khalifé, P., Song, G., Champney, E.R., Mielcarz, D.W., Geoghegan, J.C., Burton, D.R., Andrabi, R., Bloom, J.D., Walker, L.M., (2022), Evolution of antibody immunity following Omicron BA.1 breakthrough infection, https://doi.org/10.1101/2022.09.21.508922
    https://www.biorxiv.org/content/10.1101/2022.09.21.508922v1.full.pdf
  32. Muik, A., Lui, B.G., Bacher, M., Wallisch, A.-K., Toker, A. Finlayson, A. Krüger, K., Ozhelvaci, O., Grikscheit, K., Hoehl, S., Ciesek, S., Türeci, Ö., Sahin, U., (2022), Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5., https://doi.org/10.1101/2022.08.02.502461
    https://www.biorxiv.org/content/10.1101/2022.08.02.502461v1.full.pdf

                                                                        ❖  ❖  ❖
    ‍
  33. Vanden Bossche, G., (2022), Immuno-epidemiologic ramifications of the C-19 mass vaccination experiment: Individual and global health consequences
    www.voiceforscienceandsolidarity.org/scientific-blog/immuno-epidemiologic-ramifications-of-the-c-19-mass-vaccination-experiment-individual-and-global-health-consequences
  34. Vanden Bossche, G., (2022), Instead of generating herd immunity, C-19 mass vaccination triggers a chain reaction of new pandemics and epidemics
    https://www.voiceforscienceandsolidarity.org/scientific-blog/c-19-mass-vaccination-triggers-a-chain-reaction-of-new-pandemics-and-epidemics
  35. Vanden Bossche, G., (2022), A Fairy Tale of Pandemics,
    https://www.voiceforscienceandsolidarity.org/scientific-blog/a-fairy-tale-of-pandemics
  36. Collier, A.Y., Miller, J., Hachmann, N.P., McMahan, K., Liu, J., Apraku Bondzie, E., Gallup, L., Rowe, M., Schonberg, E., Thai, S., Barrett, J., Borducchi, E.N., Bouffard, E., Jacob-Dolan, C., Mazurek, C.R., Mutoni, A., Powers, O., Sciacca, M., Surve, N., VanWyk, H., Wu, C., Barouch, D.H., (2022), Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters, https://doi.org/10.1101/2022.10.24.513619
    https://www.biorxiv.org/content/10.1101/2022.10.24.513619v1.full.pdf
  37. Wang, Q., Bowen, A., Valdez, R., Gherasim, C., Gordon, A., Liu L., Ho, D.D., (2022), Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot., https://doi.org/10.1101/2022.10.22.513349
    https://www.biorxiv.org/content/10.1101/2022.10.22.513349v1.full.pdf
  38. Collier, A.Y., Miller, J., Hachmann, N.P., McMahan, K., Liu, J., Bondzie, E.A., Gallup, L., Rowe, M., Schonberg, E., Thai, S., Barrett, J., Borducchi, E.N., Bouffard, E., Jacob-Dolan, C., Mazurek, C.R. Mutoni, A., Powers, O., Sciacca, M., Surve, N., VanWyk, H., Wu, C., Barouch, D.H., (2023), Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters, New England Journal of Medicine, 10.1056/NEJMc2213948
    https://www.nejm.org/doi/pdf/10.1056/NEJMc2213948?articleTools=true
  39. Vanden Bossche, G., (2022), Novel bivalent C-19 vaccines: What does common immunological sense predict in regard to their impact on the C-19 pandemic?
    https://www.voiceforscienceandsolidarity.org/scientific-blog/novel-bivalent-c-19-vaccines-what-does-common-immunological-sense-predict-in-regard-to-their-impact-on-the-c-19-pandemic
  40. Lempp, F.A., Soriaga, L.B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y-J., Bianchi, S., Walls, A.C., Bowen, J.E. Zhou, J., Kaiser, H., Joshi, A., Agostini, M., Meury, M., Dellota, E Jr., Jaconi, S., Cameroni, E., Martinez-Picado, J., Vergara-Alert, J., Izquierdo-Useros, N., Virgin, H. W., Lanzavecchia, A., Veesler, D., Purcell, L. A. Telenti, A., Corti, D., (2021), Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies., https://doi.org/10.1038/s41586-021-03925-1
    https://www.nature.com/articles/s41586-021-03925-1.pdf
  41. Perez-Zsolt, D., Muñoz-Basagoiti, J., Rodon, J., Elosua-Bayes, M., Raïch-Regué, D., Risco, C., Sachse, M., Pino, M., Gumber, S., Paiardini, M., Chojnacki, J., Erkizia, I., Muñiz-Trabudua, X., Ballana, E., Riveira-Muñoz, E., Noguera-Julian, M., Paredes, R., Trinité, B., Tarrés-Freixas, F., Blanco, I., … Izquierdo-Useros, N. (2021). SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cellular & molecular immunology, 18(12), 2676–2678. https://doi.org/10.1038/s41423-021-00794-6
    https://pubmed.ncbi.nlm.nih.gov/34782760/ =
  42. Perez-Zsolt, D., Muñoz-Basagoiti, J., Rodon, J., Elousa, M., Raïch-Regué, D., Risco, C., Sachse, M., Pino, M., Gumber, S., Paiardini, M., Chojnacki, J., Erkizia, I., Muñiz, X., Ballana, E., Riveira-Muñoz, E., Noguera, M., Paredes, R., Trinité, B., Tarrés-Freixas, F., Blanco, I., Guallar, V., Carrillo, J., Blanco, J., Telenti, A., Heyn, H., Segalés, J., Clotet, B., Martinez-Picado, J., Vergara-Alert, J., Izquierdo-Useros, N., (2021), Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses, bioRxiv 2021.05.11.443572; doi: https://doi.org/10.1101/2021.05.11.443572
    https://www.biorxiv.org/content/10.1101/2021.05.11.443572v1
  43. Vanden Bossche, G., (2021), When anti-S(pike) antibodies against Omicron can no longer sustain the narrative, why not resort to T cells?
    https://www.voiceforscienceandsolidarity.org/scientific-blog/when-anti-s-pike-antibodies-against-omicron-can-no-longer-sustain-the-narrative-why-not-resort-to-t-cells
  44. Madu, I. G., Roth, S. L., Belouzard, S., & Whittaker, G. R. (2009). Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. Journal of virology, 83(15), 7411–7421. https://doi.org/10.1128/JVI.00079-09
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2708636/
  45. Lin, D. Y., Gu, Y., Xu, Y., Zeng, D., Wheeler, B., Young, H., Sunny, S. K., & Moore, Z. (2022). Effects of Vaccination and Previous Infection on Omicron Infections in Children. The New England journal of medicine, 387(12), 1141–1143. https://doi.org/10.1056/NEJMc2209371
    https://pubmed.ncbi.nlm.nih.gov/36069811/  
  46. Agerer, B., Koblischke, M., Gudipati, V., Montaño-Gutierrez, L. F., Smyth, M., Popa, A., Genger, J. W., Endler, L., Florian, D. M., Mühlgrabner, V., Graninger, M., Aberle, S. W., Husa, A. M., Shaw, L. E., Lercher, A., Gattinger, P., Torralba-Gombau, R., Trapin, D., Penz, T., Barreca, D., … Bergthaler, A. (2021). SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses. Science immunology, 6(57), eabg6461. https://doi.org/10.1126/sciimmunol.abg6461
    https://pubmed.ncbi.nlm.nih.gov/33664060/
  47. Dolton, G., Rius, C., Hasan, S., Wall, A., Szomolay, B., Behiry, E., Whalley, T., Southgate, J., Fuller, A., Morin, T., Topley, K., Rong Tan, L., Goulder, P.J.R., Spiller, O.B., Rizkallah, P.J., Jones, L.C., Connor, T.R., Sewell, A.K., (2022), Emergence of immune escape at dominant SARS-CoV-2 killer T cell epitope., Cell, Volume 185, Issue 16, Pages 2936-2951.e19, https://doi.org/10.1016/j.cell.2022.07.002.
    https://www.sciencedirect.com/science/article/pii/S0092867422008492
  48. Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradnik, J., Uriu, K., Fujita, S., Kosugi, Y., Wang, L., Tsuda, M., Kishimoto, M., Ito, H., Suzuki, R., Shimizu, R., Begum, M. M., … Sato, K. (2022). Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell, 185(21), 3992–4007.e16. https://doi.org/10.1016/j.cell.2022.09.018
    https://www.biorxiv.org/content/10.1101/2022.12.27.521986v1.full.pdf
  49. Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K., Sadamasu, K., Kimura, I., Ito, J., Wu, J.,  Iwatsuki-Horimoto, K., Ito, M., Yamayoshi, S., Ozono, S., Erika PButlertanaka, Tanaka, Y.L., Shimizu, R., Shimizu, K.,  Yoshimatsu, K., RyokoKawabata, Sakaguchi, T., Tokunaga, K., Yoshida, I., Asakura, H., Nagashima, M.,  Kazuma, Y., Nomura, R., Horisawa, Y., Yoshimura, K., Takaori-Kondo, A., Imai, M., The Genotype to Phenotype Japan (G2P-Japan) Consortium, Nakagawa, S. Ikeda, T., Fukuhara, T., Kawaoka, Y., Sato, K., (2021), SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity., ioRxiv 2021.06.17.448820; doi: https://doi.org/10.1101/2021.06.17.448820
    https://www.biorxiv.org/content/10.1101/2021.06.17.448820v1.full.pdf
  50. Qu, P., Faraone, J.N., Evans, J.P., Zou, X., Zheng, Y., Carlin, C., Bednash, J.S., Lozanski, G., Mallampalli, R.K., Saif, L.J., Oltz, E.M., Mohler, P.J., Gumina, R.J., Liu, S., (2022), Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants., bioRxiv 2022.05.16.492158; doi: https://doi.org/10.1101/2022.05.16.492158
    https://www.biorxiv.org/content/10.1101/2022.05.16.492158v1.full.pdf
  51. Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradnik, J., Uriu, K., Fujita, S., Kosugi, Y., Wang, L., Tsuda, M., Kishimoto, M., Ito, H., Suzuki, R., Shimizu, R., Begum, M. M., … Sato, K. (2022). Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell, 185(21), 3992–4007.e16. https://doi.org/10.1016/j.cell.2022.09.018
    https://www.cell.com/action/showPdf?pii=S0092-8674%2822%2901190-4
  52. Chumakov, K., Avidan, M. S., Benn, C. S., Bertozzi, S. M., Blatt, L., Chang, A. Y., Jamison, D. T., Khader, S. A., Kottilil, S., Netea, M. G., Sparrow, A., & Gallo, R. C. (2021). Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proceedings of the National Academy of Sciences of the United States of America, 118(21), e2101718118. https://doi.org/10.1073/pnas.2101718118
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166166/
  53. Parmar, K., Siddiqui, A., & Nugent, K. (2021). Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity. The American journal of the medical sciences, 361(6), 683–689. https://doi.org/10.1016/j.amjms.2021.03.003
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938189/
  54. Brogna, C., Brogna, B., Bisaccia, D. R., Lauritano, F., Marino, G., Montano, L., Cristoni, S., Prisco, M., & Piscopo, M. (2022). Could SARS-CoV-2 Have Bacteriophage Behavior or Induce the Activity of Other Bacteriophages?. Vaccines, 10(5), 708. https://doi.org/10.3390/vaccines10050708
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143435/
  55. Li, L., Han, P., Huang, B.et al., (2022), Broader-species receptor binding and structural bases of Omicron SARS-CoV-2 to both mouse and palm-civet ACE2s. Cell Discov 8, 65, https://doi.org/10.1038/s41421-022-00431-0
    https://www.nature.com/articles/s41421-022-00431-0
  56. Qu, P., Faraone, J.N., Evans, J.P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J.S., Lozanski, G., Mallampalli, R.K., Saif, L.J., Oltz, E.M., Mohler, P.J., Gumina, R.J., Liu, S.-L., (2022), Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants, https://doi.org/10.1101/2022.05.16.492158
    https://www.biorxiv.org/content/10.1101/2022.05.16.492158v1.full.pdf
  57. Arora, P., Cossmann, A., Schulz, S.R., Morillas Ramos, G., Stankov, M.V., Jäck, H-M., Behrens, G.M.N., Pöhlmann, S., Hoffmann, M., (2023), Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage., The Lancet, DOI: https://doi.org/10.1016/S1473-3099(22)00831-3
    https://www.thelancet.com/action/showPdf?pii=S1473-3099%2822%2900831-3

further reading on website

‍

‍